China’s hepatitis B drug race enters critical phase as Cosunter commits 587 million yuan
The Chinese drugmaker is stepping up investment in its hepatitis B pipeline as GSK’s bepirovirsen wins regulatory…
Latest
- Yatsen turns to AI and biotech as demand grows for targeted beauty products
- China’s hepatitis B drug race enters critical phase as Cosunter commits 587 million yuan
- ByteDance wants its AI to tap your screen. App developers are pushing back
- Lenovo shares hit record high as AI infrastructure drives earnings growth
- Wanda founder Wang Jianlin gets a face-saving exit for his HYROX sports bet
